Mycosyst (Fluconazole)

Fluconazole, the active ingredient in Mycosyst, is an azole antifungal presented as an oral dosage form for systemic use. It treats a range of fungal infections, including candidiasis, cryptococcal meningitis and dermatophyte infections, in adult and pediatric patients as prescribed.

GNH USA supplies Mycosyst as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory support for import and distribution. Clients benefit from reliable logistics and consistent product availability.

Fluconazole is an azole antifungal used to treat fungal infections affecting various organ systems.

- Candidiasis (oropharyngeal, esophageal, vaginal): eradicates Candida species, relieving symptoms and preventing systemic spread. - Cryptococcal meningitis: penetrates the central nervous system to reduce fungal burden and improve clinical outcomes. - Dermatophyte infections: treats skin and nail fungal infections caused by Trichophyton, Microsporum and Epidermophyton species.

Fluconazole may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea: mild stomach upset, often transient and not requiring treatment. - Headache: occasional tension‑type headache that may improve with analgesics. - Diarrhea: loose stools that usually resolve with continued therapy. - Abdominal pain: cramping or discomfort in the stomach area, generally mild. - Rash: mild skin erythema or itching without systemic involvement.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or hepatitis, requiring monitoring of liver function. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis, demanding immediate medical attention. - Cardiac arrhythmias: QT prolongation leading to irregular heartbeat, especially with interacting drugs. - Anaphylaxis: rare but potentially life‑threatening allergic reaction needing emergency care.

Before prescribing fluconazole, clinicians should consider several precautionary measures to ensure safe use.

- Liver function: assess baseline hepatic enzymes and monitor during therapy. - Renal impairment: adjust dose in patients with severe kidney dysfunction. - Drug interactions: review concomitant medications for potential CYP450 interactions. - Pregnancy and lactation: evaluate risks versus benefits as safety data are limited. - Allergies: avoid use in individuals with known hypersensitivity to azole antifungals. - Store at ambient temperature: keep below 25 °C, retain original packaging and protect from moisture.

Fluconazole interacts with several medicines; understanding the interaction level guides clinical decisions.

Major Interactions (Avoid): - QT‑prolonging agents (e.g., quinidine, amiodarone): may cause serious cardiac arrhythmias. - CYP3A4 substrates with narrow therapeutic index (e.g., cyclosporine, tacrolimus): risk of toxicity. - Warfarin: increased anticoagulant effect leading to bleeding.

Moderate Interactions (Monitor Closely): - Oral contraceptives: reduced efficacy, consider alternative contraception. - Statins metabolized by CYP2C9 (e.g., fluvastatin): possible increased muscle toxicity. - Phenytoin: altered plasma levels of both drugs, requiring dose adjustments.